- Conditions
- Prostate Cancer
- Interventions
- 2mg INO-5150 and electroporation device CELLECTRA®-5P, 8.5mg INO-5150 and electroporation device CELLECTRA®-5P, 2mg INO-5150 plus 1mg INO-9012 and electroporation device CELLECTRA®-5P, 8.5mg INO-5150 plus 1mg INO-9012 and electroporation device CELLECTRA®-5P, Electroporation using CELLECTRA®-5P
- Biological · Device
- Lead sponsor
- Inovio Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 90 Years · Male only
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 10
- States / cities
- Baltimore, Maryland • Detroit, Michigan • Omaha, Nebraska + 7 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–2
of 2
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Head and Neck Cancer, Human Papilloma Virus
- Interventions
- MEDI0457, CELLECTRA®5P device, Durvalumab
- Drug · Device
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 14
- States / cities
- San Francisco, California • Orlando, Florida • Atlanta, Georgia + 10 more